The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Eganian R.A.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

Statins in the primary prevention of coronary heart disease (a review)

Authors:

Eganian R.A.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2013;16(3): 37‑43

Views: 2477

Downloaded: 41

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Eganian RA. Statins in the primary prevention of coronary heart disease (a review). Russian Journal of Preventive Medicine. 2013;16(3):37‑43. (In Russ.)

 
МСФ на ЯМ
Close metadata
Recommended articles:
Primary prevention of colo­rectal cancer and technologies for its implementation into practical health care. Russian Journal of Preventive Medi­cine. 2024;(6):111-117
Possibilities of coro­nary artery calcification asse­ssment for cardiovascular risk stra­tification. Russian Journal of Preventive Medi­cine. 2024;(9):117-122
The improvement of the specialized medi­cal care for patients with peri­pheral arte­rial athe­rosclerosis in the Yaro­slavl region. Russian Journal of Preventive Medi­cine. 2024;(12):16-23
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45
Enda­rterectomy from supe­rficial femo­ral artery in patients with type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):285-293
Influence of gene­tic poly­morphism of the chemokine rece­ptor CCR5 on clinical course of coro­nary artery disease and resu­lts of percutaneous coro­nary inte­rventions. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(4):401-409
The value of reva­scularisation of athe­rosclerotic lesions of the inno­minate artery at the asymptomatic stage of the disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):72-82
Fore­nsic characteristic of sudden death cases in subjects with meta­bolic syndrome. Fore­nsic Medi­cal Expe­rtise. 2024;(4):54-57
Pharmacogenetic testing for personalized statin prescription in Moscow. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):49-55
Giant popliteal artery aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):115-119

With the advent of new classes of lipid-lowering agents and with the improvement of their efficacy-evaluating procedures, interest has been aroused in their use for the primary prevention of cardiovascular diseases. Statins have been of special interest. Problems in this respect may arise when true primary prevention is identified. The determination of a total cardiovascular risk in apparently healthy individuals must be of prime importance. It is precisely these criteria that should serve as the basis for the use of statins in primary prevention.

Keywords:

statins
atherosclerosis
primary prevention

Authors:

Eganian R.A.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

List of references:

  1. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980; 2 : 379-385.
  2. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 3: 351-364.
  3. Aronov D.M., Lupanov V.P. Ateroskleroz i koronarnaya bolezn' serdtsa. M 2005; 248.
  4. Bubnova M.G., Aronov D.M., Perova N.V. Lipidkorrigiruyushchaya effektivnost' nizkoi dozy atorvastatina u bol'nykh sakharnym diabetom 2-go tipa. Sakharnyi diabet 2003; 1: 30-34.
  5. Natsional'nye rekomendatsii po diagnostike i korrektsii narushenii lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Kardiovask ter i prof 2007; 6: 6: Prilozhenie 3.
  6. Koziolova N.A. Kombinirovannaya lipidkorrigiruyushchaya terapiya: vybor strategii i taktiki. Kardiovask ter i prof 2010; 9: 4: 107-115.
  7. Brief M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., Blechacz B., Bassler D., Wei X., Sharman A., Whitt I., Alves da Silva S., Khalid Z., Nordmann A.J., Zhou Q., Walter S.D., Vale N., Bhatnagar N., O'Regan C., Mills E.J., Bucher H.C., Montori V.M., Guyatt G.H. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338: b92.
  8. Sharrett A.R., Ding J., Criqui M.H., Saad M.F., Liu K., Polak J.F., Folsom A.R., Tsai M.Y., Burke G.L., Szklo M. Smoking, diabetes, and blood cholesterol differ in their association with subclinical atherosclerosis; the Multiethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2006; 186: 2: 441-447.
  9. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 3: 309-316.
  10. Arima H., Yonemoto K., Doi Y., Ninomiya T., Hata J., Tanizaki Y., Fukuhara M., Matsumura K., Iida M., Kiyohara Y. Development and validation of a cardiovascular risk prediction model for Japanese: the Hisayama study. Hypertens Res 2009; 32: 12: 1119-1122.
  11. Thompson G.R., Holyer J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol 1995; 6: 6: 386-388.
  12. Thompson G.R. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis 1997; 131: 1: 1-5.
  13. Goff D.C. Jr, Bertoni A.G., Kramer H., Bonds D., Blumenthal R.S., Tsai M.Y., Psaty B.M. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006; 113: 5: 647-656.
  14. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., Ahearn D., Kuvin J.T., Karas R.H. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006; 98: 9: 1231-1233.
  15. Brewer H.B. Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92: 4B: 23K-29K.
  16. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 7: 498-511.
  17. Stalenhoef A.F., Ballantyne C.M., Sarti C., Murin J., Tonstad S., Rose H., Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005; 26: 24: 2664-2672.
  18. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 14: 1001-1009.
  19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 19: 1349-1357.
  20. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 20: 1615-1622.
  21. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 15: 1440-1445.
  22. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 19: 2292-2297.
  23. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr, Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 21: 2195-2207.
  24. Ridker P.M., MacFadyen J.G., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J.; JUPITER Study Group. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulat Cardiovasc Qual Outcomes 2009; 2: 6: 616-623.
  25. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
  26. Sever P., Dahlöf B., Poulter N., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S., Kristinsson A., McInnes G., Mehlsen J., Nieminem M., O'Brien E., Ostergren J.; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 24: 2982-2988.
  27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
  28. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., Westendorp R.G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
  29. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., Cain V.A., Blasetto J.W.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160.
  30. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiol Fail 1997; 3: 4: 249-254.
  31. Schuster H., Fox J.C. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5: 5: 1187-1200.
  32. Blasetto J.W., Stein E.A., Brown W.V., Chitra R., Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patientsand in special population groups. Am J Cardiol 2003; 91:5A: 3S-10S.
  33. Hunninghake D.B., Stein E.A., Bays H.E., Rader D.J., Chitra R.R., Simonson S.G., Schneck D.W. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004; 15: 2: 115-123.
  34. Nishiwaki M., Ikewaki K., Ayaori M., Mizuno K., Ohashi Y., Ohsuzu F., Ishikawa T., Nakamura H.; MEGA Study Group. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of the MEGA Study. J Cardiol 2013; 61: 3: 196-200.
  35. Hung C.Y., Lin C.H., Loh el-W., Ting C.T., Wu T.J. CHADS(2) score, statin therapy, and risks of atrial fibrillation. Am J Med 2013; 126: 2: 133-140.
  36. Kosoglou T., Meyer I., Veltri E.P., Statkevich P., Yang B., Zhu Y., Mellars L., Maxwell S.E., Patrick J.E., Cutler D.L., Batra V.K., Affrime M.B. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe andsimvastatin. Br J Clin Pharmacol 2002; 54: 3: 309-319.
  37. Farnier M., Averna M., Missault L., Vaverkova H., Viigimaa M., Massaad R., Vandormael K., Johnson-Levonas A.O., Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009; 63: 4: 547-559.
  38. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E.M.; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 13: 1556-1565.
  39. Bale B.F., Doneen A.L., Drueding R., Charland S.L. Aggressive risk factor modification in patients with subclinical atherosclerosis reduces plaque burden and regresses carotid artery wall thickness. Atherosclerosis 2006; 7: Suppl: 161.
  40. Crouse J.R. 3rd, Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O'Leary D.H., Grobbee D.E., Bots M.L.; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297: 12: 1344-1353.
  41. Fleg J.L., Mete M., Howard B.V., Umans J.G., Roman M.J., Ratner R.E., Silverman A., Galloway J.M., Henderson J.A., Weir M.R., Wilson C., Stylianou M., Howard W.J. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52: 25: 2198-2205.
  42. Blumenthal R.S., Michos E.D. The HALTS trial - halting atherosclerosis or halted too early? N Engl J Med 2009; 361: 22: 2178-2180.
  43. Sharma K., Blaha M.J., Blumenthal R.S., Musunuru K. Clinical and research applications of carotid intima-media thickness. Am J Cardiol 2009; 103: 9: 1316-1320.
  44. Finn A.V., Kolodgie F.D., Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arteriosler Thromb Vasc Biol 2010; 30: 2: 177-181.
  45. ACCORD Study Group; ACCORD Eye Study Group, Chew E.Y., Ambrosius W.T., Davis M.D., Danis R.P., Gangaputra S., Greven C.M., Hubbard L., Esser B.A., Lovato J.F., Perdue L.H., Goff D.C. Jr, Cushman W.C., Ginsberg H.N., Elam M.B., Genuth S., Gerstein H.C., Schubart U., Fine L.J. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 17: 1563-1574.
  46. Kukharchuk V.V. Medikamentoznaya terapiya narushenii lipidnogo obmena u bol'nykh sakharnym diabetom: reshennye i nereshennye voprosy. Consilium Medicum. Bolezni serdtsa i sosudov 2006; 2: 2.
  47. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 22: 1583-1592.
  48. Simopoulos A.P. Omega-3 fatty acids in the prevention-management of cardiovascular disease. Can J Physiol Pharmacol 1997; 75: 3: 234-239.
  49. Ray K.K., Seshasai S.R., Erqou S., Sever P., Jukema J.W., Ford I., Sattar N. Statins and all-cause mortality in high-risk primary prevention: a metaanalysis of 11 randomized controlled trials involving 65,229 participants. Arch Inter Med 2010; 170: 12: 1024-1031.
  50. Brugts J.J., Deckers J.W. Statin prescription in men and women at cardiovascular risk: to whom and when? Curr Opin Cardiol 2010; 25: 5:484-489.
  51. Tonelli M., Lloyd A., Clement F., Conly J., Husereau D., Hemmelgarn B., Klarenbach S., McAlister F.A., Wiebe N., Manns B.; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a metaanalysis. CMAJ 2011; 183: 16: E1189-E1202.
  52. Statins for the primary prevention of cardiovascular disease (Review). Copyright 2012. The Cochrane Collaboration. Published by John Wiley & Sons Ltd 2012.
  53. Yusuf S., Lonn E., Bosch J. Lipid lowering for primary prevention. Lancet 2009; 374: 1152-1155.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.